Prasugrel vs ticagrelor in acute coronary syndromes

Slides:



Advertisements
Similar presentations
August 30, 2009 at CET. Ticagrelor compared with clopidogrel in patients with acute coronary syndromes – the PLATO trial.
Advertisements

When PCI in NSTEMI? Giuseppe Biondi Zoccai, MD Department of Medico-Surgical Sciences and Biotechnologies Sapienza University of Rome.
After cardiac arrest: emergency coronary angiography for all? Giuseppe Biondi-Zoccai, MD Sapienza University of Rome, Italy
Bonferroni: Friend or Foe? Multiple Testing in Cardiovascular Medicine Dhruv S. Kazi, MD, MSc AHA Cardiovascular Outcomes Research Fellow Stanford University.
STENT THROMBOSIS: WHICH IMPACT IN REAL CLINICAL PRACTICE? Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino Ospedale S. Giovanni Battista.
Canadian Diabetes Association Clinical Practice Guidelines Acute Coronary Syndromes and Diabetes Chapter 26 Jean-Claude Tardif, Phillipe L. L’Allier, David.
North of Tyne anti-platelet guidelines: use in primary care Jane S Skinner Consultant Community Cardiologist.
Oral Antiplatelet Agents: A Cornerstone of Therapy for Atherothrombotic Disease Aspirin and clopidogrel: - Reduce the risks of myocardial infarction, ischemic.
Khawar Kazmi. Thrombosis LipidsInflammation Thrombus Platelets and thrombin Quiescent Plaque Plaque rupture PATHOGENESIS ACUTE CORONARY SYNDROME.
Pharmacology in Acute Coronary Syndromes: Anti-platelet Agents Tim Kinnaird, University Hospital Wales, Cardiff and Vale NHS Trust.
Bleeding with antiplatelet agents Giuseppe Biondi-Zoccai, MD Sapienza University of Rome, Italy
Novel antithrombotic agents in acute coronary syndromes: better or worse than P2Y12 inhibitors Giuseppe Biondi Zoccai Sapienza Università di Roma
Giuseppe Biondi-Zoccai Division of Cardiology, University of Turin, Turin, Italy.
TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel TRITON-TIMI 38 TRITON-TIMI 38 Elliott M. Antman, MD.
Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients Paul A. Gurbel, MD.
Ticlopidine (Ticlid™) and Clopidogrel (Plavix™) Benedict R. Lucchesi, M.D., Ph.D. Department of Pharmacology University of Michigan Medical School.
Post-PCI/MI Thrombotic Events – A Plateletcentric Problem!!!!
Rob Storey Reader and Honorary Consultant in Cardiology, University of Sheffield The changing world of adjunctive pharmacology.
Clopidogrel 75 mg per day orally should be added to aspirin in patients with STEMI regardless of whether they undergo reperfusion.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Applications of bivalirudin in interventional cardiology
Karlis TRUSINSKIS Interventional Cardiologist Pauls Stradins Clinical University Hospital Riga, LATVIA ANTIAGREGANTS IN ACUTE CORONARY SYNDROME.
What’s New in Acute Coronary Syndromes? Claudia Bucci BScPhm, PharmD Clinical Coordinator, Cardiovascular Diseases Sunnybrook Health Sciences Centre 13.
Vorapaxar for Secondary Prevention in Patients with Prior Myocardial Infarction Benjamin M. Scirica, MD, MPH On behalf of the TRA 2°P-TIMI 50 Steering.
Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.
Glycoprotein IIb/IIIa inhibitors and bivalirudin: under utilised? Azfar Zaman Freeman Hospital Newcastle-upon-Tyne.
Mechanical devices for cardiac massage: must-have or luxury? Mechanical devices for cardiac massage: must-have or luxury? Giuseppe Biondi-Zoccai, MD Sapienza.
Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine Update on Novel Antiplatelet Agents Under.
COMPLETE REVASCULARIZATION IN ELDERLY - When it’s contraindicated
Pocket Guide to Anticoagulation in AF & Dual Antiplatelet Therapy in ACS Rumi Jaumdally 2015 This brief presentation will summarise the recently published.
1 Advanced Angioplasty London, England 27 January, 2006 Jörg Michael Rustige,MD Medical Director Lilly Critical Care Europe, Geneva.
Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
TRITON TIMI-38 STEMI cohort Primary End Point (CV death, MI and stroke at 15 months) Adapted from Montalescot et al. ESC Time (days)
Copyright ©2007 American Heart Association Wiviott SD et al, Circulation 2007 Copyright ©2007 American Heart Association Wiviott SD et al, Circulation.
The Effect of Cangrelor and Access Site on Ischemic and Bleeding Events – Insights from CHAMPION PHOENIX J. Antonio Gutierrez, MD, MHS, Robert A. Harrington,
Giuseppe Biondi Zoccai University of Turin, Turin, Italy METCARDIO, Turin, Italy BMS & Sanofi Aventis Sponsored.
Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.
Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.
TRITON TIMI-38 STEMI cohort Clopidogrel Under Fire: Is Prasugrel in Primary PCI or Recent MI Superior? Insights From TRITON-TIMI-38 Gilles Montalescot,
Adapted from Angiolillo DJ et al. Am J Cardiol. 2006;97: Individual Response Variability to Dual Antiplatelet Therapy in the Steady State Phase of.
Acute Coronary Syndrome: In Hospital Antiplatelet Management
Prasugrel in all ACS Patients! Giuseppe Biondi-Zoccai, MD Sapienza University of Rome, Italy
The Big Antiplatelet Debate: Why I Prefer Ticagrelor Over Prasugrel
New Anti-platelet Agents
Heparin Should be the First-line Therapy for Patients with ACS/AMI
Antiplatelet therapy for STEMI: The Case for Clopidogrel
Should We Preload STEMI Patients with Antiplatelet Therapy?
SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.
The Big Antiplatelet Debate Why I Prefer Prasugrel Over Ticagrelor
11/12/2018 CYP2C19-Clopidogrel Development of these slides was supported by funding from the IGNITE Network. When using or adapting any of these slides.
11/12/2018 CYP2C19-Clopidogrel Development of these slides was supported by funding from the IGNITE Network. When using or adapting any of these slides.
Gilles Montalescot, ACTION Study Group, Paris
EUCLID Trial design: Patients with peripheral arterial disease (PAD) were randomized to ticagrelor 90 mg twice daily (n = 6,930) vs. clopidogrel 75 mg.
Figure 2 Binding properties of P2Y12-receptor inhibitors
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Giuseppe Biondi Zoccai University of Turin, Turin, Italy
Nat. Rev. Cardiol. doi: /nrcardio
ANTARCTIC Trial design: Patients with acute coronary syndrome undergoing stenting were randomized to tailored antiplatelet therapy (n = 435) versus conventional.
Would you recommend extending DAPT >1 year post-MI?
Figure 6 Pharmacodynamic profile of switching between clopidogrel and ticagrelor therapy: results from the RESPOND study Figure 6| Pharmacodynamic profile.
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Why I Prefer Ticagrelor
Benefits of complete coronary revascularization – Counterpoint: what are you talking about? Giuseppe Biondi Zoccai, MD University of Modena and Reggio.
What oral antiplatelet therapy would you choose?
Presents to PCI-capable hospital and undergoes
Roberta Rossini et al. JCIN 2018;11:
Is Prasugrel Superior To Ticagrelor For The Treatment Of Patients With Acute Coronary Syndromes? Evidence From A 32,893-Patient Adjusted Indirect Comparison.
Figure 3. Trials and possible strategies for un-guided and guided DAPT de-escalation. The figure shows studies and strategies on DAPT de-escalation approaches.
Presentation transcript:

Prasugrel vs ticagrelor in acute coronary syndromes Giuseppe Biondi-Zoccai, MD Sapienza University of Rome, Italy giuseppe.biondizoccai@uniroma1.it

Learning goals Scope of the problem Prasugrel Ticagrelor Reconciling the evidence

Learning goals Scope of the problem Prasugrel Ticagrelor Reconciling the evidence

The platelet: our common foe Anticoagulants PAR inhibitors <- <- <- Aspirin P2Y12 inhibitors <- <- IIb/IIIa inhibitors Jackson et al, Nat Rev Drug Discov 2003

Aspirin Oral drug Irreversibly inactivates cyclooxygenase Inhibits production of thromboxane A2 (TXA) Limits TXA-mediated platelet activation and aggregation Does not impact on other activation pathways and has highly variable response

Clopidogrel Oral drug Irreversibly inactivates the P2Y12 platelet receptor for ADP Limits P2Y12-mediated platelet activation and aggregation Does not impact on other activation pathways and has highly variable response

State-of-the-art aspirin plus clopidogrel Rx Clopidogrel 600 mg loading, then 150 mg/day for 6 days followed by 75 mg/day Clopidogrel 300 mg loading , then 75 mg/day CV death, MI, or stroke Mehta et al, Lancet 2010

Treatment alternatives Tan et al, Cardiovasc Ther 2012

Learning goals Scope of the problem Prasugrel Ticagrelor Reconciling the evidence

Prasugrel Oral drug Irreversibly inactivates the P2Y12 platelet receptor for ADP (more potently and predictably than clopidogrel) Limits P2Y12-mediated platelet activation and aggregation Does not impact on other activation pathways 60 mg loading, 10 mg maintenance (5 mg if >75 years or <60 kg) Aspirin dose is irrelevant

Clopidogrel, prasugrel and ticagrelor Tan et al, Cardiovasc Ther 2012

Prasugrel has an established and favorable risk-benefit profile Wiviott et al, New Engl J Med 2008

Risk stratification is of course key Montalescot et al, Lancet 2009

Dose adjustment is possible Erlinge et al, J Am Coll Cardiol 2012

Loading with both clopidogrel and prasugrel is not prohibitive Loh et al, Am J Cardiol 2013

Particularly risk-beneficial in diabetics Wiviott et al, Circulation 2008

Wiviott et al, Circulation 2008 And even more so in IDDM Wiviott et al, Circulation 2008

Less clear-cut benefit in medically managed ACS patients CV death, MI, or stroke HR=0.91 (0.79-1.05), p=0.21 Wiviott et al, Circulation 2008

Last but not least Are you afraid of increased neoplastic risk after assuming prasugrel? Do you know how long does it take to develop cancer after you are exposed to a nuclear bomb (e.g. Hiroshima)? Any purported association between prasugrel and cancer risk in TRITON-TIMI 38 patently lacks biologic plausibility

Learning goals Scope of the problem Prasugrel Ticagrelor Reconciling the evidence

Ticagrelor Oral drug Reversibly antagonizes the P2Y12 platelet receptor for ADP Thus limits P2Y12-mediated platelet activation and aggregation Does not impact on other activation pathways 180 mg load, 90 mg x 2/day maintenance Must be associated with 75-100 mg/day aspirin

Clopidogrel, prasugrel and ticagrelor Tan et al, Cardiovasc Ther 2012

Steadily increasing benefit in all ACS Wallentin et al, New Engl J Med 2009

Remarkable safety profile vs clopidogrel Wallentin et al, New Engl J Med 2009

Benefits across the board All patients* Ticagrelor (n=9,333) Clopidogrel (n=9,291) HR for (95% CI) p value Primary objective, n (%) CV death + MI + stroke 864 (9.8) 1,014 (11.7) 0.84 (0.77–0.92) <0.001 Secondary objectives, n (%) Total death + MI + stroke CV death + MI + stroke + ischaemia + TIA + arterial thrombotic events Myocardial infarction CV death Stroke 901 (10.2) 1,290 (14.6) 504 (5.8) 353 (4.0) 125 (1.5) 1,065 (12.3) 1,456 (16.7) 593 (6.9) 442 (5.1) 106 (1.3) 0.88 (0.81–0.95) 0.84 (0.75–0.95) 0.79 (0.69–0.91) 1.17 (0.91–1.52) 0.005 0.001 0.22 Total death 399 (4.5) 506 (5.9) 0.78 (0.69–0.89) Wallentin et al, New Engl J Med 2009

Non-CABG bleeding also ↑ by ticagrelor Wallentin et al, New Engl J Med 2009

But this is offset by ↓ CABG-related bleeds Cannon et al, Lancet 2010

Are bradyarrhythmias major issues? Holter monitoring at first week Ticagrelor (n=1,451) Clopidogrel (n=1,415) p value Ventricular pauses ≥3 seconds, % Ventricular pauses ≥5 seconds, % 5.8 2.0 3.6 1.2 0.01 0.10 Holter monitoring at 30 days (n= 985) (n=1,006) 2.1 0.8 1.7 0.6 0.52 0.60 Bradycardia-related event, % (n=9,235) (n=9,186) Pacemaker Insertion Syncope Bradycardia Heart block 0.9 1.1 4.4 0.7 4.0 0.87 0.08 0.21 1.00 Wallentin et al, New Engl J Med 2009

What about dyspnea and cancer? All patients Ticagrelor (n=9,235) Clopidogrel (n=9,186) P value Dyspnoea, % Any With discontinuation of study treatment 13.8 0.9 7.8 0.1 <0.001 Neoplasms arising during treatment, % Malignant Benign 1.4 1.2 0.2 1.7 1.3 0.4 0.17 0.69 0.02 Wallentin et al, New Engl J Med 2009

What about creatinine and uric acid? All patients Ticagrelor (n=9,235) Clopidogrel (n=9,186) P value* % increase in creatinine from baseline At 1 month At 12 months Follow-up visit 10  22 11  22 8  21 9  22 <0.001 0.59 % increase in uric acid from baseline 14  46 15  52 7  43 7  44 7  31 8  48 0.56 Wallentin et al, New Engl J Med 2009

Benefits are highly consistent but… Cannon et al, Lancet 2010

Learning goals Scope of the problem Prasugrel Ticagrelor Reconciling the evidence

Biondi-Zoccai et al, Int J Cardiol 2011 First and foremost: both prasugrel and ticagrelor are lifesaving vs clopidogrel Biondi-Zoccai et al, Int J Cardiol 2011

Adjusted indirect comparison Biondi-Zoccai et al, Int J Cardiol 2011

Adjusted indirect comparison Biondi-Zoccai et al, Int J Cardiol 2011

Adjusted indirect comparison Biondi-Zoccai et al, Int J Cardiol 2011

Do you trust platelet responsiveness assays? Alexopoulos et al, J Am Coll Cardiol 2012

Biondi-Zoccai et al, BMJ 2008 (but also Gurbel et al, JAMA 2012; I personally don’t Biondi-Zoccai et al, BMJ 2008 (but also Gurbel et al, JAMA 2012; Collet et al, NEJM 2012; Gaglia et al, Cardiovasc Revasc Med 2013; etc)

Alexopoulos et al, Circ Cardiovasc Interv 2012 Even if you believe… Alexopoulos et al, Circ Cardiovasc Interv 2012

Reconciling the evidence Biondi-Zoccai et al, Curr Vasc Pharmacol 2012

Take home messages Both prasugrel and ticagrelor are superior to clopidogrel in acute coronary syndromes. Prasugrel is best avoided in those at moderately high or high bleeding risk (e.g. prior stroke/TIA) or when coronary intervention is not likely. A 5 mg/day dose should be used in the elderly or for weight <60 kg. Ticagrelor is best avoided in those at high bleeding risk, and must be associated with low-dose aspirin. Awaiting the ACCOAST trial, ticagrelor appears more appealing than prasugrel for NSTEACS if antiplatelet Rx is to be instituted in the ER, but equipoise holds for STEMI.

Many thanks for your attention For these slides and further ones on similar topics feel free to visit: www.metcardio.org/slides.html For additional details or queries feel free to contact me directly: giuseppe.biondizoccai@uniroma1.it